NovaBay Pharmaceuticals Inc (NBY)
0.681
-0.04
(-5.39%)
USD |
NYAM |
Nov 22, 16:00
0.673
-0.01
(-1.17%)
Pre-Market: 20:00
NovaBay Pharmaceuticals Cash from Financing (Quarterly): 2.089M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.089M |
| June 30, 2024 | -0.492M |
| March 31, 2024 | -0.597M |
| December 31, 2023 | -0.026M |
| September 30, 2023 | -0.577M |
| June 30, 2023 | 2.513M |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 3.035M |
| September 30, 2022 | 1.703M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | -0.105M |
| December 31, 2021 | 14.80M |
| September 30, 2021 | 0.219M |
| June 30, 2021 | 1.775M |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.005M |
| September 30, 2020 | 6.013M |
| June 30, 2020 | 4.108M |
| March 31, 2020 | -0.364M |
| December 31, 2019 | -0.654M |
| September 30, 2019 | 6.852M |
| June 30, 2019 | 2.52M |
| March 31, 2019 | 2.984M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2018 | -0.006M |
| March 31, 2018 | 5.603M |
| December 31, 2017 | 0.065M |
| September 30, 2017 | 0.146M |
| June 30, 2017 | 0.038M |
| March 31, 2017 | -0.048M |
| December 31, 2016 | 0.858M |
| September 30, 2016 | 9.824M |
| June 30, 2016 | 4.746M |
| March 31, 2016 | 3.994M |
| December 31, 2015 | 3.568M |
| September 30, 2015 | 0.337M |
| June 30, 2015 | 7.043M |
| March 31, 2015 | 4.653M |
| December 31, 2014 | 0.42M |
| September 30, 2014 | 0.359M |
| June 30, 2014 | 0.051M |
| March 31, 2014 | 6.556M |
| December 31, 2013 | 7.018M |
| September 30, 2013 | 1.832M |
| June 30, 2013 | 0.447M |
| March 31, 2013 | 0.03M |
| December 31, 2012 | 8.186M |
| September 30, 2012 | 1.314M |
| June 30, 2012 | 0.007M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.654M
Minimum
Dec 2019
14.80M
Maximum
Dec 2021
1.672M
Average
0.0025M
Median
Cash from Financing (Quarterly) Benchmarks
| Palatin Technologies Inc | -0.127M |
| iBio Inc | -0.162M |
| Theriva Biologics Inc | 3.716M |
| Oragenics Inc | 3.766M |
| Nanoviricides Inc | 1.710M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -2.061M |
| Cash from Investing (Quarterly) | -0.002M |
| Free Cash Flow | -4.812M |
| Free Cash Flow Per Share (Quarterly) | -0.5561 |
| Free Cash Flow to Equity (Quarterly) | -1.418M |
| Free Cash Flow Yield | -479.8% |